Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study.

摘要: Abstract This study examined whether zonisamide (ZNS) cotreatment delays dopamine transporter (DAT) reduction on SPECT in Parkinson disease (PD) patients. The participants met the following criteria: (i) age ≥ 40 years; (ii) HY stage = 2 or 3; (iii) average specific binding ratio (SBR) ≥2.00; (iv) levodopa administration without a prior history of ZNS use before first DAT-SPECT (baseline). Attending physicians initially determined (25 mg/day) should be used not. Levodopa and other anti-PD medications were not restricted. second (endpoint) was conducted 1.2 ± 0.2 years after DAT-SPECT. Clinicoradiological changes stage, UPDRS parts II to IV, dyskinesia subscore, SBR calculated. Statistical differences analyzed by Student's t-test, ANOVA, multilogistic analysis. improved wearing off prevented development additional selegiline, entacapone, receptor agonists. endpoint reduced significantly non-ZNS group compared baseline (P